Profound Medical recently announced that its TULSA-PRO® device has earned 510(k) clearance by the US Food and Drug Administration (FDA) to ablate prostate tissue. This is the first transurethral ultrasound device approved in the US, and it allows physicians to predictably ablate whole-gland or partial prostate tissue.
The Foundation recently hosted a workshop to discuss the potential value of adding tractography as a targeting tool for transcranial focused ultrasound treatments.
The traditional path to bring new therapies from the laboratory bench to the patients' bedside is relatively straight, but why isn't it more successful?
University of Michigan researchers were awarded a four-year, $2.4M grant from the National Institute of Biomedical Imaging and Bioengineering to study transcranial histotripsy.
Nathan McDannold, PhD, and team found temporary but notable functional MRI changes in rats undergoing focused ultrasound—based blood-brain barrier opening.
Mark Carol, CEO of SonaCare Medical, writes about the challenges for medical device companies that have regulatory approval as they await Medicare coverage for their treatments.
The Foundation has posted a brief presentation about its Reimbursement Seminars to help treatment sites ensure that they are billing correctly for focused ultrasound procedures.
